Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
18.71
+0.11 (0.59%)
At close: Nov 20, 2024, 4:00 PM
18.13
-0.58 (-3.10%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $19.65M in the twelve months ending June 30, 2024, down -92.33% year-over-year. In the fiscal year ending September 30, 2023, Arrowhead Pharmaceuticals had annual revenue of $240.74M, down -1.03%.
Revenue (ttm)
$19.65M
Revenue Growth
-92.33%
P/S Ratio
109.98
Revenue / Employee
$37,425
Employees
525
Market Cap
2.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardent Health Partners | 5.71B |
| iRhythm Technologies | 560.03M |
| UFP Technologies | 461.85M |
| Twist Bioscience | 312.97M |
| LeMaitre Vascular | 213.03M |
| Geron | 29.48M |
| Centessa Pharmaceuticals | 6.85M |
| IDEAYA Biosciences | 3.92M |
ARWR News
- 2 days ago - Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
- 2 days ago - Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - Business Wire
- 15 days ago - Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - Business Wire
- 16 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - Business Wire
- 20 days ago - Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire